RU2337106C2 - Смесь аналогов циклоспорина и ее применение в качестве иммуномодулирующего агента - Google Patents
Смесь аналогов циклоспорина и ее применение в качестве иммуномодулирующего агента Download PDFInfo
- Publication number
- RU2337106C2 RU2337106C2 RU2004110941/04A RU2004110941A RU2337106C2 RU 2337106 C2 RU2337106 C2 RU 2337106C2 RU 2004110941/04 A RU2004110941/04 A RU 2004110941/04A RU 2004110941 A RU2004110941 A RU 2004110941A RU 2337106 C2 RU2337106 C2 RU 2337106C2
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- isomer
- isomeric mixture
- pharmaceutical composition
- cyclosporin
- Prior art date
Links
- 0 C[C@](CC=CC=C)C([C@@](C=O)N(C)I**)O Chemical compound C[C@](CC=CC=C)C([C@@](C=O)N(C)I**)O 0.000 description 2
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34620101P | 2001-10-19 | 2001-10-19 | |
| US60/346,201 | 2001-10-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2004110941A RU2004110941A (ru) | 2005-08-10 |
| RU2337106C2 true RU2337106C2 (ru) | 2008-10-27 |
Family
ID=23358378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004110941/04A RU2337106C2 (ru) | 2001-10-19 | 2002-10-17 | Смесь аналогов циклоспорина и ее применение в качестве иммуномодулирующего агента |
Country Status (38)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141648B2 (en) | 2001-10-19 | 2006-11-28 | Isotechnika Inc. | Synthesis of cyclosporin analogs |
| EP1816138A1 (en) * | 2001-10-19 | 2007-08-08 | Isotechnika,Inc. | Cyclosporine analogue mixtures and their use as immunomodulating agents |
| EP1603512A2 (en) | 2003-03-17 | 2005-12-14 | Albany Molecular Research, Inc. | Novel cyclosporins |
| TW200505946A (en) * | 2003-04-08 | 2005-02-16 | Hoffmann La Roche | Process for preparation of cyclosporin a analog |
| US7378391B2 (en) | 2004-09-29 | 2008-05-27 | Amr Technology, Inc. | Cyclosporin alkyne analogues and their pharmaceutical uses |
| WO2006039164A2 (en) | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Novel cyclosporin analogues and their pharmaceutical uses |
| WO2006041631A2 (en) | 2004-10-06 | 2006-04-20 | Amr Technology, Inc. | Novel cyclosporin alkynes and their utility as pharmaceutical agents |
| JP2008524122A (ja) * | 2004-12-17 | 2008-07-10 | イソテクニカ インコーポレーテッド | シクロスポリン類似体の代謝体 |
| KR101273681B1 (ko) * | 2005-10-26 | 2013-06-25 | 아스텔라스세이야쿠 가부시키가이샤 | 신규 시클릭 펩티드 화합물 |
| US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| AU2008250254B2 (en) * | 2007-05-02 | 2012-08-16 | Astellas Pharma Inc. | New cyclic peptide compounds |
| ES2667945T3 (es) | 2007-10-08 | 2018-05-16 | Aurinia Pharmaceuticals Inc. | Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR |
| RU2361604C1 (ru) * | 2007-10-29 | 2009-07-20 | Федеральное агентство по высокотехнологичной медицинской помощи Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии" (ФГУ УрНИИДВиИ Росмедтехнологий) | Способ лечения атопического дерматита |
| EP2440185B1 (en) | 2009-06-09 | 2015-04-08 | Aurinia Pharmaceuticals Inc. | Topical drug delivery systems for ophthalmic use |
| GB0912584D0 (en) * | 2009-07-20 | 2009-08-26 | Ucl Business Plc | Cyclosporin conjugates |
| WO2012079172A1 (en) | 2010-12-15 | 2012-06-21 | Isotechnika Pharma Inc. | Cyclosporine analogue molecules modified at amino acid 1 and 3 |
| GB201222455D0 (en) | 2012-12-13 | 2013-01-30 | Perioc Ltd | Novel pharmaceutical formulations and their use in the treatment of periodontaldisease |
| JP2020510249A (ja) * | 2016-11-30 | 2020-04-02 | シュレーディンガー インコーポレイテッドＳｃｈｒｏｄｉｎｇｅｒ，Ｉｎｃ． | 化学の遷移状態を計算するためのグラフィカルユーザインタフェース |
| US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018106928A1 (en) | 2016-12-08 | 2018-06-14 | Contravir Pharmaceuticals, Inc. | Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3 |
| EP3554346B1 (en) | 2016-12-14 | 2024-01-31 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
| US10286036B2 (en) * | 2017-05-12 | 2019-05-14 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| IL296586B1 (en) | 2020-03-26 | 2026-04-01 | Farsight Medical Tech Shanghai Co Ltd | Cyclophilin inhibitors and their uses |
| EP4201952A1 (en) | 2021-12-21 | 2023-06-28 | Curia Spain, S.A.U. | Process for the controlled synthesis of voclosporin |
| WO2024052941A1 (en) * | 2022-09-09 | 2024-03-14 | Dr. Reddy's Laboratories Limited | Improved process for the preparation of voclosporin |
| IT202300001116A1 (it) * | 2023-01-25 | 2024-07-25 | Indena Spa | Processo per la preparazione di un intermedio utile per la sintesi di voclosporina |
| IT202300001056A1 (it) * | 2023-01-25 | 2024-07-25 | Procos Spa | Nuovo processo per la preparazione di voclosporina amorfa |
| WO2025119925A1 (en) | 2023-12-05 | 2025-06-12 | Medichem, S.A. | Process for preparing voclosporin |
| IT202300028041A1 (it) * | 2023-12-27 | 2025-06-27 | Indena Spa | Processo per la preparazione di voclosporina |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0296122A2 (en) * | 1987-06-17 | 1988-12-21 | Sandoz Ag | Cyclosporins and their use as pharmaceuticals |
| WO1999018120A1 (en) * | 1997-10-08 | 1999-04-15 | Isotechnika Inc. | Deuterated cyclosporine analogs and their use as immunomodulating agents |
| RU2131883C1 (ru) * | 1992-03-02 | 1999-06-20 | Новартис Аг | Производные циклоспорина, способ их получения и фармкомпозиция на их основе |
| RU2174405C2 (ru) * | 1997-10-23 | 2001-10-10 | Сэнгстат Медикал Корпорейшн | Композиция циклоспорина для перорального введения (варианты) и способ достижения иммуносупрессии в организме реципиента |
| RU2181055C2 (ru) * | 1996-06-19 | 2002-04-10 | Новартис Аг | Препараты, содержащие циклоспорин, в виде капсул с мягким покрытием |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4278545A (en) * | 1979-09-12 | 1981-07-14 | The Bendix Corporation | Apparatus for separating solids and liquid components |
| CH670644A5 (https=) * | 1986-12-18 | 1989-06-30 | Lonza Ag | |
| US5162540A (en) * | 1986-12-18 | 1992-11-10 | Lonza Ltd. | Process for the production of (+) biotin |
| US5972630A (en) * | 1991-08-19 | 1999-10-26 | Dade Behring Marburg Gmbh | Homogeneous immunoassays using enzyme inhibitors |
| US5750510A (en) * | 1997-04-04 | 1998-05-12 | Abbott Laboratories | 3-descladinose-2,3-anhydroerythromycin derivatives |
| US5939406A (en) * | 1997-07-21 | 1999-08-17 | Wisconsin Alumni Research Foundation | 18-substituted-19-nor-vitamin D compounds |
| EP1816138A1 (en) * | 2001-10-19 | 2007-08-08 | Isotechnika,Inc. | Cyclosporine analogue mixtures and their use as immunomodulating agents |
| US7141648B2 (en) * | 2001-10-19 | 2006-11-28 | Isotechnika Inc. | Synthesis of cyclosporin analogs |
-
2002
- 2002-10-17 EP EP07106871A patent/EP1816138A1/en not_active Withdrawn
- 2002-10-17 CN CNB02820798XA patent/CN100344648C/zh not_active Expired - Lifetime
- 2002-10-17 IL IL16076202A patent/IL160762A0/xx unknown
- 2002-10-17 NZ NZ531945A patent/NZ531945A/en not_active IP Right Cessation
- 2002-10-17 MY MYPI20023885A patent/MY187182A/en unknown
- 2002-10-17 DE DE60227686T patent/DE60227686D1/de not_active Expired - Lifetime
- 2002-10-17 CA CA2727642A patent/CA2727642C/en not_active Expired - Lifetime
- 2002-10-17 WO PCT/CA2002/001560 patent/WO2003033527A2/en not_active Ceased
- 2002-10-17 AU AU2002331510A patent/AU2002331510B2/en not_active Expired
- 2002-10-17 BR BR0213659-7A patent/BR0213659A/pt not_active IP Right Cessation
- 2002-10-17 UY UY27502A patent/UY27502A1/es not_active Application Discontinuation
- 2002-10-17 DK DK02767028T patent/DK1436322T3/da active
- 2002-10-17 MX MXPA04003624A patent/MXPA04003624A/es active IP Right Grant
- 2002-10-17 ES ES02767028T patent/ES2310604T3/es not_active Expired - Lifetime
- 2002-10-17 JP JP2003536265A patent/JP2005511538A/ja not_active Withdrawn
- 2002-10-17 AR ARP020103918A patent/AR036853A1/es not_active Application Discontinuation
- 2002-10-17 EP EP02767028A patent/EP1436322B1/en not_active Expired - Lifetime
- 2002-10-17 PT PT02767028T patent/PT1436322E/pt unknown
- 2002-10-17 PY PY200200225477A patent/PY0225477A/es unknown
- 2002-10-17 KR KR1020047005721A patent/KR100992850B1/ko not_active Expired - Lifetime
- 2002-10-17 SI SI200230742T patent/SI1436322T1/sl unknown
- 2002-10-17 AT AT02767028T patent/ATE401339T1/de active
- 2002-10-17 HR HRP20040353AA patent/HRP20040353B1/hr not_active IP Right Cessation
- 2002-10-17 CA CA2460685A patent/CA2460685C/en not_active Expired - Lifetime
- 2002-10-17 ME MEP-2008-780A patent/ME00487B/me unknown
- 2002-10-17 PL PL370501A patent/PL210697B1/pl unknown
- 2002-10-17 PY PY200200225478A patent/PY0225478A/es unknown
- 2002-10-17 RU RU2004110941/04A patent/RU2337106C2/ru active
-
2004
- 2004-03-05 IL IL160762A patent/IL160762A/en active IP Right Grant
- 2004-03-23 ZA ZA2004/02270A patent/ZA200402270B/en unknown
- 2004-03-26 MA MA27598A patent/MA26337A1/fr unknown
- 2004-04-14 EC EC2004005061A patent/ECSP045061A/es unknown
- 2004-04-14 EC EC2004005060A patent/ECSP045060A/es unknown
- 2004-04-14 EC EC2004005059A patent/ECSP045059A/es unknown
- 2004-04-16 TN TNP2004000069A patent/TNSN04069A1/en unknown
- 2004-04-19 CO CO04035672A patent/CO5570682A2/es not_active Application Discontinuation
- 2004-05-14 NO NO20042029A patent/NO331745B1/no not_active IP Right Cessation
-
2008
- 2008-10-13 CY CY20081101130T patent/CY1108410T1/el unknown
-
2009
- 2009-06-11 JP JP2009140608A patent/JP5272140B2/ja not_active Expired - Lifetime
-
2010
- 2010-07-02 JP JP2010151859A patent/JP2011006417A/ja active Pending
- 2010-12-23 US US12/977,602 patent/US20110092669A1/en not_active Abandoned
-
2013
- 2013-01-31 JP JP2013017448A patent/JP2013136597A/ja active Pending
-
2014
- 2014-03-18 US US14/217,827 patent/US20140288266A1/en not_active Abandoned
-
2022
- 2022-10-14 NL NL301200C patent/NL301200I2/nl unknown
- 2022-10-14 BE BE2022C547C patent/BE2022C547I2/nl unknown
- 2022-10-14 FR FR22C1051C patent/FR22C1051I2/fr active Active
- 2022-10-14 LT LTPA2022521C patent/LTC1436322I2/lt unknown
- 2022-10-14 NO NO2022042C patent/NO2022042I1/no unknown
- 2022-10-14 FI FIC20220041C patent/FIC20220041I1/fi unknown
- 2022-10-14 CY CY2022030C patent/CY2022030I2/el unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0296122A2 (en) * | 1987-06-17 | 1988-12-21 | Sandoz Ag | Cyclosporins and their use as pharmaceuticals |
| RU2131883C1 (ru) * | 1992-03-02 | 1999-06-20 | Новартис Аг | Производные циклоспорина, способ их получения и фармкомпозиция на их основе |
| RU2181055C2 (ru) * | 1996-06-19 | 2002-04-10 | Новартис Аг | Препараты, содержащие циклоспорин, в виде капсул с мягким покрытием |
| WO1999018120A1 (en) * | 1997-10-08 | 1999-04-15 | Isotechnika Inc. | Deuterated cyclosporine analogs and their use as immunomodulating agents |
| RU2174405C2 (ru) * | 1997-10-23 | 2001-10-10 | Сэнгстат Медикал Корпорейшн | Композиция циклоспорина для перорального введения (варианты) и способ достижения иммуносупрессии в организме реципиента |
Non-Patent Citations (1)
| Title |
|---|
| Eberle M.K. et al.: "Modifications of the MeBmt Side Chain of Cyclosporin A" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, Vol.5, №15, 03.08.1995. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2337106C2 (ru) | Смесь аналогов циклоспорина и ее применение в качестве иммуномодулирующего агента | |
| JP2005511538A5 (https=) | ||
| JP4149905B2 (ja) | サイクロスポリンａおよび４０−ｏ−（２−ヒドロキシエチル）−ラパマイシンを含む移植拒絶、自己免疫疾患または炎症性状態の処置用医薬組成物 | |
| US20240100005A1 (en) | Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune Diseases | |
| NL195028C (nl) | Cyclosporinebevattend farmaceutisch preparaat. | |
| RU2615397C2 (ru) | Фармацевтические композиции на основе соли микофеноловой кислоты с энтеросолюбильным покрытием | |
| US20090215813A1 (en) | Histone deacetylase inhibitors as immunosuppressants | |
| Pescovitz et al. | Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients | |
| JPH02255623A (ja) | 新規シクロスポリン製剤 | |
| SK97199A3 (en) | Oral cyclosporin formulations | |
| EP0170623B1 (en) | Novel pharmaceutical use of (nva)2-cyclosporine | |
| CZ411691A3 (cs) | Deriváty cyklosporinu | |
| TW200522975A (en) | Pharmaceutical composition for use in the treatment of an inflammatory autoimmune disease or condition | |
| US5514714A (en) | Methods and polycyclic aromatic compound containing compositions for treating T-cell-mediated diseases | |
| WO1993017039A1 (en) | Iso-cyclosporin salts | |
| JPH06172168A (ja) | 免疫抑制剤 | |
| US6355639B1 (en) | Reverse prenyl compounds as immunosuppressants | |
| Graeb et al. | Cyclosporine: 20 years of experience at the University of Munich | |
| WO1993008797A1 (en) | Hypericin compositions for treating t-cell mediated diseases | |
| Kuiper et al. | Cyclosporine-induced anaphylaxis | |
| JP2002533401A (ja) | シクロスポリン溶液 | |
| Koch et al. | Leflunomide: is there a place for its use in transplantation? | |
| RU2800933C2 (ru) | Режим дозирования видофлудимуса для использования в профилактике или лечении хронических воспалительных и/или аутоиммунных заболеваний | |
| KR100847565B1 (ko) | 디아세트아미도콜히친 및/또는 디아세트아미도디히드로티오콜히친을 함유하는 약제학적 조성물 및 이들 화합물의 제조방법 | |
| CN103896812A (zh) | N，n’－二环己基－n－高级脂肪酸酰脲类似物及其制药用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20160304 |
|
| PD4A | Correction of name of patent owner |